Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, ...

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

These aren't for the faint of heart.

Recursion Pharmaceuticals combines artificial intelligence, automation, and biotechnology research across multiple ...

Recursion Pharmaceuticals (RXRX) is back in focus as investors weigh fresh updates on its AI-driven drug discovery platform, along with progress in key clinical assets REC-1245 and REC-4881 and ...

Nous Research has released Hermes Mixture of Agents 2.0 (MoA 2.0), an update to its open-source Hermes Agent framework that ...

Autonomous AI post-training reached frontier scale for the first time: NVIDIA researchers published a paper showing an AI ...

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from ...

What are Fugu and Fugu Ultra, the AI systems through which Japan's Sakana AI is betting on 'One Model To Command Them All' ...

Once again, China is showing that it can catch up with the big boys very quickly.